Brief: Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv
19/02/2025 12:04
Feb 19 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES ANNOUNCES INITIAL SAFETY AND
ANTIVIRAL
ACTIVITY OF PBGENE-HBV IN THE ELIMINATE-B CLINICAL TRIAL
* PRECISION BIOSCIENCES INC - PBGENE-HBV SAFE AND WELL
TOLERATED
IN INITIAL STUDY
Source text: ID:nBw9lDyPZa
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing